Weekly Recap: ZEVASKYN growth, expanded access and pipeline licensing
Abeona Therapeutics, Inc. (NASDAQ:ABEO) posted $11.4M ZEVASKYN revenue, up 31% QoQ, while expanding treatment reach—12 patients, seven centers covering ~40% of addressable patients and >95% payer coverage—and advanced its pipeline via AAV204 licensing to Beacon, Ultragenyx’s UX111 PDUFA, and acquir…